Dr. Agarwal on latest COSMIC-021 data for atezolizumab/cabozantinib in mCRPC

Video

Neeraj Agarwal, MD, discusses updated data from the phase 1b COSMIC-021 trial, which showed that the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) continued to demonstrate clinically meaningful activity in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer (mCRPC).

Agarwal, a professor of Medicine at the Huntsman Cancer Institute, University of Utah, and an investigator on the COSMIC-021 trial, also discusses the ongoing phase 3 randomized, open-label, CONTACT-02 study (NCT04446117), which is exploring cabozantinib plus atezolizumab versus second novel hormone therapy (NHT; abiraterone acetate, enzalutamide, etc) in patients with mCRPC who previously received 1 NHT to treat metastatic castration-sensitive prostate cancer, non-metastatic CRPC, or mCRPC.

Related Videos
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Man talking with doctor | © DragonImages - stock.adobe.com
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
blur image background of corridor in hospital or clinic image | Image Credit: © whyframeshot - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.